- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Stay current with the latest press releases from within the industry.
Active Biotech advances ANYARA into Phase III clinical trial.
Release issued 13th May 2008
Active Biotech advances ANYARA into Phase III clinical trial. Lund, Sweden, May 13, 2008 - An interim analysis has been performed in Active Biotech AB's (OMX Nordic: ACTI) ongoing Phase II/III clinical study of ANYARA, in patients with advanced renal cell cancer (see attached press release).
Company details
If you want to find out more about the company visit Active Biotech profile.
Latest Active Biotech press releases
(15th April 2008) Preclinical data presented for Active Biotech's ANYARA technology
(24th October 2007) Active Biotech's Cancer Project ANYARA Proven Safe in Combination with Taxotere®
(10th August 2007) FDA Approves IND for Phase II Studies of TASQ
(26th July 2007) EMEA Grants Orphan Drug Status to Active Biotech's Cancer Treatment ANYARA
(9th June 2007) Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us